In some countries, this medicine may only be approved for veterinary use.
Ingredient matches for Metofane
Methoxyflurane is reported as an ingredient of Metofane in the following countries:
- United States
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Methoxyflurane is reported as an ingredient of Metofane in the following countries:
International Drug Name Search
Generic Name: chlorothiazide and reserpine (klor oh THYE a zide and re SER peen)
Brand Names: Diupres-250, Diupres-500
Reserpine lowers blood pressure by decreasing the amount of certain chemicals in your body. This allows your blood vessels (veins and arteries) to relax and your heart to beat more slowly and easily.
Chlorothiazide is a thiazide diuretic (water pill). It helps to lower your blood pressure and decrease edema (swelling) by increasing the amount of salt and water you lose in your urine.
Chlorothiazide and reserpine is used to lower high blood pressure.
Chlorothiazide and reserpine may also be used for purposes other than those listed in this medication guide.
Tell your doctor and dentist that you are taking this medication before having surgery.
You must not take chlorothiazide and reserpine if you
have peptic ulcer disease (stomach ulcers);
have ulcerative colitis;
are suffering from depression (especially if you have suicidal thoughts);
are receiving electroconvulsive shock therapy; or
are taking a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate).
Before taking this medication, tell your doctor if you have
gallstones or other stomach problems,
diabetes,
gout,
a collagen vascular disease such as systemic lupus erythematosus,
high cholesterol or triglyceride levels,
pancreatitis,
asthma, or
any type of heart disease.
You may require a lower dose or special monitoring during therapy with chlorothiazide and reserpine if you have any of the conditions listed above.
Take chlorothiazide and reserpine exactly as directed. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
See also: Chlorothiazide and reserpine dosage (in more detail)
Take the missed dose as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed and take only your next regularly scheduled dose. Do not take a double dose of this medication.
Symptoms of a chlorothiazide and reserpine overdose include low blood pressure (fainting, dizziness, weakness); sleepiness; uncontrollable hand, leg, or arm movements; a slow pulse; low body temperature; diarrhea; increased urination; vomiting; and slow breathing.
Avoid a diet high in salt. Too much salt will cause your body to retain water and will decrease the effects of chlorothiazide.
Do not let yourself become overheated in hot weather or during exercise, and use caution if you have a fever. These situations increase the effects of chlorothiazide and reserpine in your body, and you may become very dizzy.
Do not take any over the counter cough, cold, allergy, sleep, or diet medications without first asking your doctor or pharmacist. These will interfere with your chlorothiazide and reserpine therapy.
Use caution when you are driving, operating machinery, or performing other hazardous activities until you know how chlorothiazide and reserpine affects you. If it makes you dizzy or drowsy, avoid these activities.
Tell your doctor and dentist that you are taking this medication before having surgery.
an allergic reaction (difficulty breathing, closing of your throat, swelling of your lips, tongue or face, hives);
a very irregular heartbeat;
heart failure (shortness of breath, swelling of ankles or legs, sudden weight gain of 5 pounds or more);
unusual fatigue;
abnormal bleeding or bruising;
yellow skin or eyes;
confusion;
fainting;
uncontrollable hand, arm, or leg movements;
chest pain; or
little or no urine.
Other, less serious side effects are more likely to occur. Continue to take chlorothiazide and reserpine and talk to your doctor if you experience
fatigue or drowsiness;
dizziness (avoid standing up too quickly and use caution when performing hazardous activities);
anxiety, depression, or nightmares;
diarrhea, nausea, vomiting, or an acid stomach (take chlorothiazide and reserpine with food or milk if it upsets your stomach);
abdominal pain;
stuffy nose or a dry mouth (sucking on ice chips or sugarless hard candy may relieve a dry mouth);
blurred vision;
headache;
tingling or numbness in your arms, legs, hands, or feet;
excessive urination;
muscle weakness or cramps;
increased hunger or thirst;
weight gain;
sensitivity to sunlight; or
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
Usual Adult Dose for Hypertension:
Initial dose: 1-2 tablets (chlorothiazide/reserpine 250 mg-0.125 mg) orally once or twice a day or
1 tablet (chlorothiazide/reserpine 500 mg-0.125 mg) orally once or twice a day.
Should conform to the dosages of the individual components established during titration.
Do not take reserpine and chlorothiazide if you are taking a monoamine oxidase inhibitor (MAOI), or if you have taken one in the last 14 days. MAOIs, used to treat depression, include isocarboxazid (Marplan), phenelzine (Nardil), and tranylcypromine (Parnate).
Before taking this medication, tell your doctor if you are taking any of the following medicines:
digoxin (Lanoxin) or quinidine (Cardioquin, Quinidex, Quinora, Quinaglute), which will increase the risk that you will experience an irregular heartbeat when it is taken with chlorothiazide and reserpine;
barbiturates such as phenobarbital (Luminal, Solfoton), amobarbital (Amytal), and secobarbital (Seconal), which may cause extreme sleepiness or dizziness if taken with reserpine and chlorothiazide;
narcotic pain relievers such as codeine (Tylenol #3, Tylenol #4, others), propoxyphene (Darvon, Darvocet, Wygesic), oxycodone (Percodan, Percocet, Tylox), meperidine (Demerol), morphine (MS Contin, Duramorph, others), and others, which also may cause extreme sleepiness or dizziness if taken with reserpine and chlorothiazide;
steroid medications such as hydrocortisone (Hydrocortone, Cortef), prednisone (Deltasone, Orasone), prednisolone (Delta Cortef, Prelone), methylprednisolone (Medrol), betamethasone (Celestone), dexamethasone (Decadron, Hexadrol), and others, which may increase the side effects of chlorothiazide;
prescription and over-the-counter cough, cold, allergy, diet, and sleeping pills, any of which may contain drugs that increase your blood pressure and heart rate and thus decrease the effects of reserpine;
the cholesterol-lowering drugs cholestyramine (Questran) and colestipol (Colestid), which may decrease the effects of chlorothiazide;
nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Motrin, Advil), ketoprofen (Orudis, Orudis, KT, Oruvail), and naproxen (Naprosyn, Anaprox, Aleve), which may also decrease the effects of chlorothiazide;
other commonly used NSAIDs, including diclofenac (Cataflam, Voltaren), etodolac (Lodine), fenoprofen (Nalfon), flurbiprofen (Ansaid), indomethacin (Indocin), ketorolac (Toradol), mefenamic acid (Ponstel), nabumetone (Relafen), oxaprozin (Daypro), piroxicam (Feldene), sulindac (Clinoril), and tolmetin (Tolectin);
oral antidiabetic drugs such as Glipizide (Glucotrol), glyburide (Micronase, Glynase, Diabeta), chlorpropamide (Diabinese), tolazamide (Tolinase) and tolbutamide (Orinase), which may not lower your blood sugar as well during therapy with chlorothiazide and reserpine (your diabetes therapy may have to be adjusted);
lithium (Lithobid, Eskalith, others), which should not be taken with chlorothiazide because serious side effects may result; or
other drugs that also lower blood pressure, including acebutolol (Sectral), atenolol (Tenormin), bisoprolol (Zebeta), carteolol (Cartrol), labetalol (Trandate, Normodyne), propranolol (Inderal), pindolol (Visken), timolol (Blocadren), benazepril (Lotensin), enalapril (Vasotec), captopril (Capoten), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), quinapril (Accupril), ramipril (Altace), amlodipine (Norvasc), bepridil (Vascor), diltiazem (Cardizem, Dilacor), felodipine (Plendil), isradipine (Dynacirc), nicardipine (Cardene), nifedipine (Adalat, Procardia), nimodipine (Nimotop), and verapamil (Calan, Veralan, Isoptin).
Drugs other than those listed here may also interact with chlorothiazide and reserpine or affect your condition. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
Chlorothiazide and reserpine is available with a prescription under the brand name Diupres. Other brand or generic formulations may also be available. Ask your pharmacist any questions you have about this medication, especially if it is new to you.
Chlorothiazide/reserpine strengths are as follows:
Diupres-250 (250 mg/ 0.125 mg)--pink, round, scored, compressed tablets
Diupres-500 (500 mg/ 0.125 mg)--pink, round, scored, compressed tablets
Generic Name: Clofarabine
Class: Antineoplastic Agents
Chemical Name: 2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine
Molecular Formula: C10H11ClFN5O3
CAS Number: 123318-82-1
Antimetabolite antineoplastic agent; synthetic purine nucleoside.1 2 4 5 6 7
Treatment of acute lymphocytic (lymphoblastic) leukemia (ALL) refractory to or relapsed after at least 2 prior therapies in patients 1–21 years of age.1 2 3 4 5 6 7 Designated an orphan drug by FDA for this use.2 3
Current indication based on induction of complete responses; randomized studies showing increased survival or other clinical benefits have not been conducted to date.1
Consult specialized references for procedures for proper handling and disposal of antineoplastics.1
Monitor respiratory status and BP during infusion, especially in patients receiving drugs that affect BP or cardiac function.1 (See Systemic Inflammatory Response Syndrome (SIRS)/Capillary Leak Syndrome under Cautions.)
Administer IV fluids continuously throughout the 5 days of clofarabine therapy to reduce the effects of tumor lysis and other adverse effects.1 Administer allopurinol if tumor lysis is expected to prevent hyperuricemia.1 (See Tumor Lysis Syndrome under Cautions.)
Administration of corticosteroids (e.g., hydrocortisone 100 mg/m2 on days 1–3) may prevent signs and symptoms of cytokine release or capillary leak syndrome.1 (See Systemic Inflammatory Response Syndrome (SIRS)/Capillary Leak Syndrome under Cautions.)
Administer by IV infusion.1
Administer IV infusion over 2 hours.1
Other drugs should not be infused through the same IV line.1
Dilute the commercially available injection for IV infusion (1 mg/mL) prior to administration.1
Filter the appropriate dose through a sterile 0.2μm filter and further dilute with 5% dextrose injection or 0.9% sodium chloride injection.1
Dosage is based on the patient’s body surface area and is calculated using the actual body weight and height of the patient before starting each cycle.1
1–21 years of age: 52 mg/m2 by IV infusion over 2 hours daily for 5 consecutive days.1
Repeat treatment cycle following recovery or return to baseline organ function, approximately every 2–6 weeks.1
Discontinue infusion immediately and initiate appropriate supportive measures if early manifestations of cytokine release or capillary leak syndrome occur.1 Consider reinstitution of therapy, generally at a lower dosage, if patient is stable and organ function has returned to baseline levels.1 (See Systemic Inflammatory Response Syndrome (SIRS)/Capillary Leak Syndrome under Cautions.)
Discontinue infusion immediately if substantial increases in serum creatinine or bilirubin concentrations occur.1 Consider reinstitution of therapy, generally at a lower dosage, once the patient is stable and organ function has returned to baseline levels.1
Discontinue infusion immediately if hypotension develops.1 Consider reinstitution of therapy at a lower dosage if hypotension was transient and resolved without pharmacologic intervention.1
No special population dosage recommendations at this time.1
No known contraindications to use of clofarabine;1 use with caution in patients with known hypersensitivity to the drug or any ingredient in the formulation.8
Administer only under supervision of clinicians qualified in use of cytotoxic therapy.1
Anticipate bone marrow suppression (usually reversible and dose dependent) with use.1
Severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) reported.1
Increased risk of developing infectious complications, including severe sepsis and opportunistic infections.1
Monitor for signs and symptoms of tumor lysis syndrome.1
Use appropriate measures (e.g., hydration, allopurinol) to prevent hyperuricemia.1
Signs and symptoms of cytokine release (i.e., tachypnea, tachycardia, hypotension, pulmonary edema) reported.1
Rapid onset of respiratory distress, hypotension, capillary leak (e.g., pleural and pericardial effusions), and multiorgan failure reported.1
Monitor closely and intervene early by discontinuance of the drug and supportive measures (e.g., corticosteroids, diuretics, and/or albumin).1
Development of SIRS or capillary leak syndrome may be fatal.1 (See Dosage under Dosage and Administration.)
May cause fetal harm; teratogenicity demonstrated in animals.1
Avoid pregnancy during therapy.1 If used during pregnancy, apprise of potential fetal hazard.1
Perform CBC, including platelet counts at regular intervals; more frequently in patients who develop cytopenias.1
Monitor hepatic and renal function prior to therapy and throughout the 5 days of clofarabine administration.1
Category D. (See Fetal/Neonatal Morbidity and Mortality under Cautions.)1
Not known whether clofarabine or its metabolites are distributed into milk.1
Discontinue nursing because of potential risk to nursing infants.1
Safety and efficacy established for treatment of relapsed or refractory ALL in patients 1–21 years of age.1
Evaluated in a limited number of children with refractory acute myeloid leukemia (AML)†.2 4 5 6 7
Safety and efficacy not established in adults >21 years of age.1
Dosage of 40 mg/m2 (given by IV infusion over 1–2 hours) daily for 5 days every 28 days was used in a phase II clinical trial in adults with relapsed or refractory hematologic malignancies.1 2 6
[64] Not studied in patients with hepatic impairment; use with caution.1
[64] If increases in bilirubin concentrations occur, withhold drug until hepatic function returns to baseline.1 Dosage adjustment may be considered.1
Not studied in patients with renal impairment; use with caution.1
If substantial increases in serum creatinine concentrations occur, withhold drug until renal function returns to baseline.1 Dosage adjustment may be considered.1
Nausea, vomiting, diarrhea, anemia, leukopenia, thrombocytopenia, neutropenia (including febrile neutropenia), infections.1
No formal drug interaction studies to date.1
Interaction with drugs that induce or inhibit CYP 450 isoenzymes not expected.1
Avoid concomitant use with nephrotoxic drugs throughout the 5 days of clofarabine administration because clofarabine is eliminated by kidneys.1
Avoid concomitant use with hepatotoxic drugs because clofarabine may cause hepatotoxicity.1
47% (mainly albumin) in pediatric patients.1
Metabolized to active 5-triphosphate metabolite.1 5
Undergoes limited hepatic metabolism (0.2%) in pediatric patients.1
Excreted in urine (49–60%) as unchanged drug in pediatric patients.1
Estimated terminal half-life about 5.2 hours in pediatric patients.1
Pharmacokinetics not studied in patients with renal or hepatic impairment.1
25°C (may be exposed to 15–30°C).1
Store diluted solutions at room temperature; discard after 24 hours.1
Inhibits DNA synthesis, inhibits ribonucleoside reductase, and has direct effects on mitochondria; these effects lead to depletion of intracellular deoxynucleotide triphosphate pools, inhibition of elongation of DNA strands during synthesis, and release of proapoptotic mitochondrial factors in both actively dividing and quiescent tumor cells.1 2 6
Advise patients about risk of dehydration secondary to vomiting and diarrhea.1
Importance of advising patients regarding appropriate measures to avoid dehydration.1
Advise patients to notify clinician immediately if symptoms of hypotension (e.g., dizziness, lightheadedness, fainting spell) or decreased urine output occurs.1
Importance of monitoring blood cell counts, renal and hepatic function.1
Necessity of advising women to use an effective method of contraception and to avoid breast-feeding while receiving clofarabine therapy.1
Importance of women informing a clinician immediately if they are or plan to become pregnant or plan to breast-feed.1 Advise pregnant women of risk to the fetus.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Parenteral | For injection, for IV infusion | 1 mg/mL (20 mg) | Clolar | Genzyme |
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions May 2006. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
1. Genzyme Corporation. Clolar (clofarabine) for intravenous infusion prescribing information. Cambridge, MA; 2005.
2. Anon. Clofarabine. Drugs R &D. 2004; 5:213-7.
3. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97 414). Rockville, MD. From FDA website (). Accessed 2005 Jan 25.
4. Jeha S, Razzouk B, Gaynon P et al. Phase II trials of clofarabine in pediatric acute leukemia. Presented at the American Society of Clinical Oncologists Annual Meeting 2005. From the ASCO website (). Abstract No. 6588. Accessed 2005 Jun 21.
5. Jeha S, Gandhi V, Chan KW et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004;103:784-9.
6. Faderl S, Gandhi V, Keating MJ et al. The role of clofarabine in hematologic and solid malignancies–development of a next-generation nucleoside analog. Cancer. 2005; 103:1985-95. [IDIS 533862] [PubMed 15803490]
7. Jeha S, Razzouk BI, Rytting ME et al. Phase II trials of clofarabine in relapsed or refractory pediatric leukemia. Presented at the American Society of Hematology Annual Meeting 2004. From the ASH website (). Abstract No. 684. Accessed 2005 Jun 30.
8. Genzyme Corporation, Cambridge, MA: personal communication.
Furosemid Kabi may be available in the countries listed below.
Furosemide is reported as an ingredient of Furosemid Kabi in the following countries:
International Drug Name Search
Generic Name: chlophedianol, guaifenesin, and phenylephrine (KLOE fe DYE a nol, gwye FEN e sin, and FEN il EFF rin)
Brand Names: Donatussin
Chlophedianol is a cough suppressant. It affects the signals in the brain that trigger cough reflex.
Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat, making it easier to cough out through your mouth.
Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).
The combination of chlophedianol, guaifenesin, and phenylephrine is used to treat stuffy nose, cough, chest congestion, and sinus congestion caused by allergies, the common cold, or the flu.
Chlophedianol, guaifenesin, and phenylephrine may also be used for purposes not listed in this medication guide.
To make sure you can safely use this medicine, tell your doctor if you have any of these other conditions:
diabetes;
epilepsy or other seizure disorder;
cough with mucus, or cough caused by emphysema, or chronic bronchitis;
enlarged prostate or urination problems; or
pheochromocytoma (an adrenal gland tumor).
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Cough or cold medicine is usually taken only for a short time until your symptoms clear up.
Do not take for longer than 7 days in a row. Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache or skin rash.
Measure liquid medicine with a special dose measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose measuring device, ask your pharmacist for one.
Since cough or cold medicine is taken when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include severe forms of some of the side effects listed in this medication guide.
Avoid taking this medication if you also take diet pills, caffeine pills, or other stimulants (such as ADHD medications). Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.
fast, slow, or uneven heart rate;
severe dizziness or anxiety, feeling like you might pass out;
mood changes, hallucinations;
severe headache;
tremor, seizure (convulsions);
fever; or
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, uneven heartbeats, seizure).
Less serious side effects may include:
mild dizziness or drowsiness;
mild headache;
diarrhea, constipation, nausea, upset stomach;
sleep problems (insomnia); or
feeling nervous or restless.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Cough and Nasal Congestion:
Chlophedianol/guaiFENesin/phenylephrine 12.5 mg-120 mg-5 mg/5 mL oral liquid:
10 mL orally every 6 to 8 hours not to exceed 40 mL daily.
Usual Pediatric Dose for Cough and Nasal Congestion:
Chlophedianol/guaiFENesin/phenylephrine 12.5 mg-120 mg-5 mg/5 mL oral liquid:
2 to 5 years: 2.5 mL orally every 6 to 8 hours not to exceed 10 mL daily.
6 to 11 years: 5 mL orally every 6 to 8 hours not to exceed 20 mL daily.
12 years or older: 10 mL orally every 6 to 8 hours not to exceed 40 mL daily.
There may be other drugs that can interact with chlophedianol, guaifenesin, and phenylephrine. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
See also: chlophedianol, guaifenesin, and phenylephrine side effects (in more detail)
Relieving symptoms of sinus congestion, runny nose, sneezing, and cough due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.
Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid is a decongestant, antihistamine, and cough suppressant combination. The decongestant works by constricting blood vessels and reducing swelling in the nasal passages. The antihistamine works by blocking the action of histamine, which helps reduce symptoms, such as watery eyes and sneezing. The cough suppressant works in the brain to help decrease the cough reflex, which reduces a dry cough.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid.
When used for long periods of time or at high doses, Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid stops working well. Do not take more than prescribed.
When used for longer than a few weeks or at high doses, some people develop a need to continue taking Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid. This is known as DEPENDENCE or addiction.
If you suddenly stop taking Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid, you may experience WITHDRAWAL symptoms including anxiety; diarrhea; fever, runny nose, or sneezing; goose bumps and abnormal skin sensations; nausea; vomiting; pain; rigid muscles; rapid heartbeat; seeing, hearing or feeling things that are not there; shivering or tremors; sweating; trouble sleeping.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; tremor; trouble sleeping; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Chlorpheniramine/Hydrocodone/Pseudoephedrine side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.
Store Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Chlorpheniramine/Hydrocodone/Pseudoephedrine Liquid. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Generic Name: carbetapentane, chlorpheniramine, ephedrine, and phenylephrine (kar BET a PEN tane, klor fen EER a meen, ee FED rin, and FEN il EFF rin)
Brand names: Rentamine, Rynatuss, Tuss Tan, ...show all 10 brand names.Rynatuss Pediatric, Rentamine Pediatric, Tuss Tan Pediatric, Tetra Tannate Pediatric, Quad Tuss Pediatric, Quad Tann Pediatric, Quad Tann
Chlorpheniramine is an antihistamine. It blocks the effects of the naturally occurring chemical histamine in the body. Chlorpheniramine prevents sneezing; itchy, watery eyes and nose; and other symptoms of allergies and hay fever.
Carbetapentane is a cough suppressant. It suppresses an area in the brain that causes coughing.
Ephedrine and phenylephrine are decongestants. They constrict blood vessels (veins and arteries). This reduces the blood flow and allows nasal passages to open up.
Carbetapentane, chlorpheniramine, ephedrine, and phenylephrine is used to treat nasal congestion, sinusitis (inflammation of the sinuses), and coughs associated with allergies, hay fever, and the common cold.
Carbetapentane, chlorpheniramine, ephedrine, and phenylephrine may also be used for purposes other than those listed in this medication guide.
Do not take more of this medication than is recommended. If your symptoms do not improve or if they worsen, talk to your doctor.
Before taking this medication, tell your doctor if you have
diabetes,
glaucoma,
heart disease or high blood pressure,
thyroid disease,
emphysema or chronic bronchitis, or
difficulty urinating or have an enlarged prostate.
You may not be able to take carbetapentane, chlorpheniramine, ephedrine, and phenylephrine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.
Take carbetapentane, chlorpheniramine, ephedrine, and phenylephrine exactly as directed. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
Do not take carbetapentane, chlorpheniramine, ephedrine, and phenylephrine for longer than 7 days in a row. If your symptoms do not improve, if they get worse, or if you have a fever, talk to your doctor.
Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication.
Symptoms of a carbetapentane, chlorpheniramine, ephedrine, and phenylephrine overdose include dry mouth, large pupils, flushing, nausea and vomiting, hyperactivity, and hallucinations.
Carbetapentane, chlorpheniramine, ephedrine, and phenylephrine may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, other antihistamines, pain relievers, anxiety medicines, seizure medicines, and muscle relaxants. Dangerous sedation, dizziness, or drowsiness may occur if carbetapentane, chlorpheniramine, ephedrine, and phenylephrine is taken with any of these medications.
Other, less serious side effects may be more likely to occur. Continue to take carbetapentane, chlorpheniramine, ephedrine, and phenylephrine and talk to your doctor or try another similar medication if you experience
dryness of the eyes, nose, and mouth;
drowsiness or dizziness;
blurred vision;
difficulty urinating; or
excitation in children.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.
Do not take other over-the-counter cough, cold, allergy, diet, pain, or sleep medications while taking carbetapentane, chlorpheniramine, ephedrine, and phenylephrine without first talking to your pharmacist or doctor. Other medications may also contain carbetapentane, chlorpheniramine, ephedrine, phenylephrine, or other similar drugs, and you may accidentally take too much of these medicines.
Carbetapentane, chlorpheniramine, ephedrine, and phenylephrine may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, other antihistamines, pain relievers, anxiety medicines, seizure medicines, and muscle relaxants. Dangerous sedation, dizziness, or drowsiness may occur if carbetapentane, chlorpheniramine, ephedrine, and phenylephrine is taken with any of these medications.
Drugs other than those listed here may also interact with carbetapentane, chlorpheniramine, ephedrine, and phenylephrine. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
See also: carbetapentane, chlorpheniramine, ephedrine, and phenylephrine side effects (in more detail)